Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBOS and PBOS in Adults With Pulmonary Tuberculosis
NCT05971602Phase 2Terminated
- Sponsor
- Gates Medical Research Institute
- Start
- Jul 2023
- Primary completion
- Feb 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of delamanid, pretomanid, bedaquiline, quabodepistat, sutezolid in pulmonary tuberculosis (TB), multidrug-resistant tuberculosis (MDR-TB), sponsored by Gates Medical Research Institute. Started Jul 2023; status: terminated.
02
Drugs
delamanidpretomanidbedaquilinequabodepistatsutezolid
03
Conditions
pulmonary tuberculosis (TB)multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT05971602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05971602.